CD8A and neoplasm: We found that the anti‐tumor effect of the combination therapy group was significantly inhibited by the removal of the CD8+ T‐cells (P < 0.01), both in the LLC‐OVA cell line and in the TC‐1‐OVA cell line (Figure S6B,C, Supporting Information).